IP Library Granted Patent US 11,202,786
Granted Patent B2
US 11,202,786 · App. 16/583,140 · Granted Dec 21, 2021

Synthetic bile acid compositions and methods

Inventors: Robert M. Moriarty (Michiana Shores, IN); Nathaniel E. David (Los Angeles, CA); Nadir Ahmeduddin Mahmood (Calabasas, CA)
Assignee: Allergan Sales, LLC
A61K31/575A61K45/06C07J9/00Y10T436/201666
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,202,786
App. No.
16/583,140
Granted
Dec 21, 2021
Kind
B2
Abstract

Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

Claims (8)

1. A method for removing localized fat in a subject in need thereof, the method comprising administering to said localized fat a therapeutically effective amount of an aqueous pharmaceutical composition comprising about 0.1% w/v to about 2% w/v deoxycholic acid (DCA), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier, wherein the deoxycholic acid has a 14 C content of less than 1 ppt.

2. The method of claim 1 , wherein the deoxycholic acid has a 14 C content of less than 0.9 ppt.

3. The method of claim 1 , wherein the deoxycholic acid has a 14 C content of 0.87 ppt.

4. The method of claim 1 , wherein the deoxycholic acid has a 14 C content of 0.88 ppt.

5. The method of claim 1 , wherein the deoxycholic acid has a 14 C content of 0.89 ppt.

6. The method of claim 1 , wherein the aqueous pharmaceutical composition is suitable for subcutaneous injection.

7. The method of claim 1 , wherein the DCA salt is sodium deoxycholate.

8. The method of claim 1 , wherein the DCA, or the pharmaceutically acceptable salt thereof, is present in the aqueous pharmaceutical composition at a concentration of about 0.5% (w/v), about 1% (w/v), or about 2% (w/v).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: MORIARTY, ROBERT M.; DAVID, NATHANIEL E.; MAHMOOD, NADIR AHMEDUDDIN
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 056905/0642 →
MERGER AND CHANGE OF NAME Recorded Jul 19, 2021
From: KYTHERA BIOPHARMACEUTICALS, LLC; ALLERGAN SALES, LLC
To: ALLERGAN SALES, LLC
Reel/Frame 056905/0852 →
CHANGE OF NAME Recorded Jul 19, 2021
From: KYTHERA BIOPHARMACEUTICALS, INC.
To: KYTHERA BIOPHARMACEUTICALS, LLC
Reel/Frame 056909/0348 →
Continuity (10)
Continuation 15986872 · May 23, 2018
Continuation 15472135 · Mar 28, 2017
Continuation 14732515 · Jun 5, 2015
Continuation 13914510 · Jun 10, 2013
Continuation 13486955 · Jun 1, 2012
Continuation 12541045 · Aug 13, 2009
Continuation In Part 12035339 · Feb 21, 2008
Provisional Application 60956875 · Aug 20, 2007
Provisional Application 60945035 · Jun 19, 2007
Related Publication 20200085843A1 · Mar 19, 2020